High-yield points
- Epilepsy in 70–90%; drug-resistant epilepsy concentrates in TSC2 .
- Prevention trials disagree:
- EPISTOP: preventive vigabatrin delayed seizures and reduced drug-resistant epilepsy ;
- PREVeNT: no cognitive or epilepsy benefit, but fewer spasms .
- Screen infants with EEG .
- Everolimus (EXIST-3): 40% responders at high trough vs 15% on placebo .
- Surgery works in selected children: about 66–69% good outcomes . Predictors differ between meta-analyses: EEG–MRI concordance and a single visible tuber favor a good outcome .
- Multiplicity of tubers is not an automatic exclusion.
- Options: tuberectomy (with peri-tuberal margin), lobar or multilobar resection, LITT, callosotomy, VNS.
Landmark papers
- EXIST-3 (French et al., Lancet 2016): a phase 3 randomized trial (366 patients) of adjunctive everolimus. Responders were 40% at high trough vs 15% on placebo .
- EPISTOP (Kotulska et al., Ann Neurol 2021): preventive vigabatrin at the first epileptiform EEG delayed the first seizure and reduced drug-resistant epilepsy at 24 months (OR 0.23) .
- Hale et al., J Neurosurg Pediatr 2025: an individual-participant meta-analysis of 1,338 children after epilepsy surgery. 66% had a good outcome, and 1 or fewer visible tubers predicted success .
Between 70% and 90% of children with tuberous sclerosis complex (TSC) develop epilepsy, frequently drug-resistant .
- Management runs from prevention in infancy to surgery for the drug-resistant child.
- Multifocal brain, but often a leading focus: TSC epilepsy is often multifocal, yet many children have a localizable leading focus, and surgery can succeed even with multifocal networks .
Who is at risk
- TSC2 genotype: in the prospective PREVeNT cohort (70 infants), every child with drug-resistant epilepsy had a TSC2 pathogenic variant .
- TSC1 variants were linked to epilepsy starting about 21 months later.
Prevention in infancy
- EPISTOP (Europe) :
- Design: 94 infants without seizures had monthly video-EEG. Vigabatrin was started either on epileptiform EEG (preventive) or after the first seizure (conventional).
- Result: preventive treatment lengthened the time to first clinical seizure: 364 vs 124 days in the randomized arm.
- At 24 months it reduced clinical seizures (OR 0.21) and drug-resistant epilepsy (OR 0.23).
- PREVeNT (USA) :
- Design: 56 infants randomized to vigabatrin at the first epileptiform EEG, or at seizure onset.
- Result: no difference in cognitive scores at 24 months, overall epilepsy, or drug-resistant epilepsy.
- Infantile spasms were less frequent and later with early vigabatrin.
- Bottom line: the international recommendations now emphasize early EEG screening . Whether to treat before seizures is still debated.
Medical therapy
- Vigabatrin is first-line for infantile spasms in TSC (standard practice; see caveats).
- Everolimus (EXIST-3) :
- Design: 366 patients aged 2–65 with treatment-resistant focal seizures, given placebo or everolimus at a low (3–7 ng/mL) or high (9–15 ng/mL) trough.
- Responders (50% or greater seizure reduction): 15.1% placebo vs 28.2% low vs 40.0% high exposure.
- Grade 3–4 adverse events: 11% vs 18% vs 24%.
- Other options: cannabidiol and the ketogenic diet are used, with VNS for those who are not surgical candidates.
Surgical evaluation
- When: refer early, once two appropriate medicines have failed.
- What the workup aims to find: a leading tuber or region. It typically includes:
- video-EEG;
- high-resolution MRI;
- functional imaging (FDG-PET, MEG, ictal SPECT);
- invasive monitoring (stereo-EEG or subdural grids) when noninvasive data are discordant or multifocal. Staged and repeat implantations are used in TSC .
- Repeat stereo-EEG (34 children with TSC who had stereo-EEG before surgery) :
- 15 needed two or more implantations.
- A single seizure focus on phase I video-EEG predicted needing only one: it was present in 68% of single-implant vs 27% of multiple-implant patients.
- Favorable outcomes (Engel I–II) at latest follow-up, among the 24 with at least a year of follow-up: 93% vs 79%, not significantly different. Multifocal networks can still be treated successfully.
- Predictors of a good outcome (Engel I–II):
- Individual-participant meta-analysis (181 children) :
- absence of generalized seizure semiology (OR 3.1);
- no or mild developmental delay (OR 7.3);
- unifocal ictal scalp EEG (OR 3.2);
- EEG–MRI concordance (OR 4.9).
- 2025 meta-analysis (1,338 children with outcome data) :
- 66% had a good seizure outcome at a median 2.5 years;
- outcome was better with 1 or fewer visible tubers on MRI (OR 4.8).
- Unexpected findings: outcome was less likely with no or mild cognitive delay (OR 0.52), or with no or unifocal interictal EEG abnormality (OR 0.36).
- The authors cautioned that the underlying studies are largely retrospective, with high risk of bias.
- Reading the two together: EEG–MRI concordance and 1 or fewer visible tubers favor success, but unifocal interictal EEG did not predict success in the larger meta-analysis . Multiple tubers or developmental delay should not by themselves exclude a child from evaluation .
Surgical options
- Tuberectomy: removes the epileptogenic tuber, often with peri-tuberal cortex, guided by EEG and imaging.
- Extended or lobar resection when the zone is larger.
- Multilobar resection or hemispherectomy: for a dominant hemisphere with a contralateral hemisphere that is relatively spared.
- Laser interstitial thermal therapy: a minimally invasive option for deep or well-defined tubers.
- In the repeat stereo-EEG series, 53% of single-implant patients were treated with laser ablation .
- TSC-specific comparative data are still limited.
- Palliative options:
- corpus callosotomy for drop attacks;
- VNS for multifocal epilepsy.
- Seizures can return from other tubers over time. Plan for long-term follow-up and possible staged surgery .
Beyond TSC: mTOR inhibition in refractory epilepsy
- RaSuRE trial (Dr. Hauptman's group, phase 1) :
- 12 children with medically and surgically refractory epilepsy received nab-rapamycin (ABI-009).
- Their etiologies included TSC, focal cortical dysplasia and hemimegalencephaly.
- The maximum tolerated dose was 20 mg/m².
- This extends the mTOR rationale to children who still seize after resection.
Related topics
- Tuberous Sclerosis Complex: the underlying disorder.
- SEGA: mTOR-inhibitor management of SEGA.
- Focal Cortical Dysplasia: related mTOR-pathway lesion.
- Intracranial EEG: staged and repeat SEEG.
- LITT in Epilepsy Surgery: ablation of tubers.
- Hemispherectomy: multilobar or hemispheric disease.
- Vagus Nerve Stimulator Implantation: step-by-step procedure.
References
- Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol 2021;89(2):304–314. doi:10.1002/ana.25956. PMID 33180985. verified
- Fallah A, Guyatt GH, Snead OC, et al. Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis. PLoS One 2013;8(2):e53565. doi:10.1371/journal.pone.0053565. PMID 23405072. verified
- Uchitel J, Fariyike O, Steeman S, et al. Utility of repeat stereotactic EEG in pediatric patients with tuberous sclerosis. Epilepsia Open 2026;11(5):1465–1477. doi:10.1002/epi4.70293. PMID 42400368. verified
- Farach LS, Richard MA, Wulsin AC, et al. Drug-resistant epilepsy in tuberous sclerosis complex is associated with TSC2 genotype: more findings from the Preventing Epilepsy Using Vigabatrin (PREVeNT) trial. Pediatr Neurol 2024;159:62–71. doi:10.1016/j.pediatrneurol.2024.06.012. PMID 39142021. verified
- Bebin EM, Peters JM, Porter BE, et al. Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol 2024;95(1):15–26. doi:10.1002/ana.26778. PMID 37638552. verified
- Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66. doi:10.1016/j.pediatrneurol.2021.07.011. PMID 34399110. verified
- French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388(10056):2153–2163. doi:10.1016/S0140-6736(16)31419-231419-2). PMID 27613521. verified
- Hale AT, Savage C, Estevez-Ordonez D, et al. Epilepsy surgery outcomes in children with tuberous sclerosis complex: a systematic review and meta-analysis. J Neurosurg Pediatr 2025;35(6):599–611. doi:10.3171/2024.12.PEDS24311. PMID 40215622. verified
- Hall K, Saneto R, Randle S, et al. Phase 1 study of ABI-009 (nab-rapamycin) for surgically refractory epilepsy (RaSuRE). Epilepsia 2025;66(11):4246–4258. doi:10.1111/epi.18555. PMID 40682748. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- The following are standard practice, not drawn from the cited abstracts:
- that early-onset and uncontrolled seizures harm development;
- that a single dominant epileptogenic tuber often drives the epilepsy;
- early epileptiform EEG predicting neurodevelopment;
- vigabatrin as first-line for spasms;
- cannabidiol, diet and VNS;
- "two medicines failed" as the referral trigger;
- the presurgical workup list;
- the surgical options other than LITT (tuberectomy margins, callosotomy).
- Reference 9 is a phase 1 safety study, not TSC-specific.
- The meta-analyses pool retrospective series with high risk of bias.
- The figure is an original schematic.